Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced ...
The firm is dropping two glioblastoma programs and cutting 49 percent of its staff to advance its gamma delta T-cell therapy INB-100 in post-transplant AML.